SUMMARY An activation of T-cells that is
Introduction
Tumor necrosis factor a (TNFa) plays a key role as a mediator of inflammation and cellular immune response. It is primarily produced and secreted by activated macrophages and monocytes and exhibits an extensive array of biologic activities. In addition to exerting a direct cytotoxic effect on tumor cells, it attracts and activates a variety of other cells, thus enhancing the inflammatory and immune processes (1) . TNFa apparently shares several bioactivities with interleukin-1 (IL-1), and it is capable of inducing IL-1 release (1). Interactions of interleukin-2 (IL-2) and its receptor (IL-2R) with TNFa have recently been described by several investigators demonstrating the induction of TNFa production in monocytes and macrophages by IL-2 (2) as well as the regulation of DNAbinding proteins by TNFa, which control IL-2 receptor gene activation in human T-cells (1, 3) .
The most characteristic features of pulmonary sarcoidosis are noncaseating granuloma and a T-lymphocyte/mononuclear phagocyte alveolitis. Despite the systemic nature of the disease, activated T-cells are observed only in the affected organs, whereas T-cells of the peripheral blood remain quiescent (4) (5) (6) (7) (8) . Evidence of T-cell activation has been provided by the spontaneous release of such mediators as y-interferon and IL-2, which recruit and activate mononuclear phagocytes, resulting in the subsequent release of IL-1 and TNFa (9, 10) . Several studies have demonstrated that macrophagederived IL-1 and TNFa play an important role in the induction and sustenance of the granuloma (11) .
Detailed analyses of the contribution of activated T-cells to the inflammatory process of sarcoidosis are provided by the literature. However, the alveolar macrophages represent the dominating cell population in sarcoid alveolitis. These cells are also activated and release mediators as well as oxidants (8) (9) (10) 12) . Regarding the activation status of peripheral blood monocytes, only a few studies are available, and conflicting results have been reported. Monitoring the spontaneous y-interferon, TNFa, and IL-1 release by monocytes, no differences were observed by several investigators between patients with sarcoidosis and normal control subjects (8, 13) . In marked contrast, an increased release of radical oxidants by sarcoid blood monocytes has been reported (14). Thus, the question of an organ-restricted activation of the mononuclear phagocytes paralleling the compartmentalized activation of sarcoid T-cells remains open. In this context we asked the following questions: (7) Is the activation of alveolar macrophages in sarcoidosis paralleled by the activation of peripheral blood monocytes? (2) Is this activation due to a stimulus from the inflammatory milieu of the lower respiratory tract or is it a constitutive property of these cells? (3) Is there a concordant activation of the alveolar macrophage/ monocyte segment as well as the T-cell segment of the immune system?
As an approach this study evaluates the spontaneous and LPS-induced TNFa and IL-1 release by alveolar macrophages and peripheral blood mononuclear cells of patients with active or inactive sarcoidosis and control subjects. The spontaneous TNFa release was compared with functional parameters of T-cell activation such as release of IL-2, expression of IL-2 receptors on the cell surface, and soluble IL-2 receptor concentration in serum. 
Methods

Study Population
The diagnosis of sarcoidosis was established in 43 patients using defined criteria, including transbronchial biopsy (15 
Northern Blot
For Northern analysis total cellular RNA was prepared using guanidine-thiocyanate lysis. RNA samples were size-fractionated by electrophoresis in 1% agarose gels containing formaldehyde and transferred to nylon filters (Genofit, Heidelberg, Germany). Hybridization was performed as described by using the 750 bp EcoRI-fragment of the coding region of human TNFa cDNA as probe. The probe was labeled by the random primer method. 
Determination of Soluble IL-2R in Serum
Statistical Analysis
Data are expressed as mean ± SEM. Comparisons were performed using the Mann Whitney U-test; p values of less than 0.05 were considered significant.
Results
Monokine Release by Alveolar Macrophages and Peripheral
Blood Mononuclear Cells Spontaneous TNFa release by AM was found to a significant greater extent in patients with active sarcoidosis than in those with inactive disease (figure 1). The average was 2,385 ± 735 pg/ml in the active versus 500 ± 212 pg/ml in the inactive group. This difference is of high statistical significance (p < 0.01). The AM of the control group released 285 ± 102 pg/ml TNFa, which is in the range of patients with inactive sarcoidosis (p > 0.02). A comparison of TNFa production by AM after stimulation with LPS also showed a significantly higher release in active compared with inactive sarcoidosis (26,416 ± 3,283 pg/ml versus 14,957 ± 3,653 pg/ml; p < 0.05) (figure 1). No difference emerged in comparing patients with inactive disease with control subjects (17,189 ± 3,670 pg/ml; p > 0.2).
Although lung macrophages from patients with active disease released significantly higher amounts of TNFa than did those from patients with inactive sarcoidosis and control subjects, the autologous PBMNC released comparable quantities in patients with sarcoidosis and in 15 healthy subjects. The spontaneous release was 384 ± 144 pg/ml in patients with active, 684 ± 186 pg/ml in those with inactive sarcoidosis, and 378 ± 186 pg/ml in control subjects (p > 0.2 for all comparisons) (figure 2). The LPS-stimulated release of TNFa by peripheral blood mononuclear cells as well did not differ between the three study groups; 4,959 ± 722 pg/ml in patients with active and 3,709 ± 1,272 pg/ml in those with inactive sarcoidosis, and 3,725 ± 449 pg/ml in normal subjects (p > 0.2, for all comparisons) (figure 2).
Spontaneous TNFa release by AM was not only observed in patients with sarcoidosis. Evaluation of TNFa release by AM in patients with idiopathic pulmonary fibrosis (IPF) (n = 9) and tuberculosis (n = 2) also demonstrated a spontaneous production of TNFa in three of nine patients with IPF (1,023/703/14,000 pg/ ml) and in the two patients with pulmonary tuberculosis (8,350 and 1,658 pg/ml). Six of nine patients with IPF and two patients with pneumonia tested negative for spontaneous TNFa release by AM.
In order to determine if the TNFa release in sarcoidosis is paralleled by the release of IL-1, we investigated both spontaneous and LPS-induced IL-1 release by AM and PBMNC of patients with active or inactive sarcoidosis. Increased spontaneous IL-1 release by AM was observed in 7 of 12 patients with active disease and in one of five with inactive disease (p < 0.05) (figure 3). The autologous PBMNC in both groups did not release any detectable 11-1 spontaneously (figure 3). After LPS-stimulation the AM of active sarcoidosis released significantly higher amounts of IL-1 than did those of inactive disease. No difference concerning the stimulated release of PBMNC was observed in either group. To check for artifacts that might alter the IL-1 data obtained by the bioassay in four patients with active disease and TNFa-positive alveolitis and in two patients with inactive disease and TNFa negative alveolitis, IL-1 (3 was measured by an ELISA. In all four patients with TNFa in the AM-supernatant IL-lp could be detected as well (20 to 4,432 pg/ml). No IL-1 was detectable in the supernatants of the two patients with inactive disease.
Time-dependent Changes of Spontaneous TNFa Release by Alveolar Macrophages of Patients with Active Sarcoidosis
To evaluate the hypothesis that heightened TNFa production by sarcoid AM in active disease may represent the consequence of a constitutive or a regulated activation of the cells, we investigated the time-dependent changes of spontaneous TNFa release 3 and 6 h after initiation of the cell culture. During the in vitro culture a considerable decrease of TNFa secretion was observed (figure 4). Although the highest amount of TNFa was released within the first 3 h after recovery of the cells, a significant decline was observed during the following 3 h. However, when the cells were cultured in the presence of a stimulus they recurrently produced high levels of TNFa.
To investigate TNFa gene expression in vitro as a function of time we evaluated AM for the presence of mRNA transcripts immediately after the cells were pg/ml/10 6 AM/24 h; 700 pg/ml corresponds to the mean plus 2 SD of 7 control subjects), 3 of 21 patients produced neither IL-2 nor TNFa, 7 of 21 released TNFa but no IL-2, and 3 of 21 released IL-2 but no TNFa.
In the inactive group alveolitis was positive in one patient for both mediators, in one patient for IL-2 only, and it was positive for any mediator in the remaining three patients. In the active group seven patients were positive for both cytokines, seven for TNFa but not for IL-2, and two were IL-2-positive but TNFa-negative.
The patients with active disease exhibited an increased CD4/CD8 ratio together with a spontaneous TNFa release by AM. However, there was no correlation between these two parameters in either the active (r = -0.08, n = 28) or the inactive group (r = -0.02, n = 10).
Discussion
TNFa is an important biologic mediator that is secreted by activated AM and monocytes. In addition to activated T-cells, AM are the second but numerically dominating cell population in sarcoidosis. Our results confirm and extend the observation of the activation of these cells as reflected by their capacity for monokine release. The data presented demonstrate that AM of patients with active sarcoidosis spontaneously release significantly higher amounts of TNFa and IL-1 than do those of patients with inactive disease or control subjects. In the present study the heightened level of spontaneous TNFa secretion by AM was paralleled by an elevated spontaneous IL-1 release in 7 of 12 of the patients with active disease tested for both monokines. Our findings are in agreement with those of other investigators, who reported a significantly higher spontaneous release of TNFa, 11-1, and y-interferon by sarcoid AM than by normal AM (8, 10, 22) . On the other hand, several investigators could not demonstrate any differences between sarcoid and normal AM regarding the spontaneous secretion of the monokines TNFa and IL-1 (9, 13, 23) . These discrepancies might be explained by monokine inhibitors, which are known to be released by AM and which might influence the detection of these small amounts of monokines by bioassays (24, 25) . As can be expected the spontaneous TNFa release by AM is not an exclusive characteristic of sarcoid alveolitis; it can be observed as well in diseases associated with AM activation by known or unknown agents such as tuberculosis and IPF. TNFa has been demonstrated to be involved in bleomycin-as well as silicainduced pulmonary fibrosis and in the generation of granulomata (11, 26) .
In marked contrast to AM, no differences between patients and control subjects emerged when the spontaneous monokine release by autologous PBMNC was tested. Our data suggest a restricted activation of the mononuclear phagocytes of the affected organ, i.e., the lung, whereas the mononuclear blood cells remain quiescent. This observation is corroborated by the study of Robinson and coworkers (8) who reported an increased y-interferon release by sarcoid AM compared with that by normal AM. This spontaneous release appeared to be compartmentalized to the lung in that the blood mononuclear cells spontaneously released little or no y-interferon (8) . An in vitro anergy of sarcoid peripheral blood cells reflected in the reduced IL-1 and IL-2 production was observed by Hudspith and coworkers (27) . Spatafora and colleagues (13) demonstrated small amounts of spontaneously produced TNFa by blood monocytes of sarcoid patients and normal control subjects, but without any difference between both. Using oxygen radical release to identify activated cells, it has been shown that sarcoid AM as well as peripheral blood monocytes are activated (12, 14) . Regarding the monokine release, our data do not confirm this activation. Thus, the exaggerated oxygen radical release suggests a systemic monocyte activation in sarcoidosis. A feasible explanation of this contradiction may be seen in the shortterm activation of the monokine gene expression after cell stimulation (1, 3).
Studies on the molecular level demonstrated that maximal expression of TNFa gene is reached within 2 h after stimulation with LPS. Cytoplasmic TNFa was detected as early as 1 h after LPS stimulation, culminating during the next 2 h and followed by a decline (recently reviewed in 1 and 3). In this context our results indicate that the heightened spontaneous TNFa release in active sarcoidosis is the consequence of an in vivo activation step just prior to the removal of the cells from the lung. Because the highest amount of TNFa is produced during the first 3 h of in vitro culture followed by a sharp decline, it can be concluded that TNFa release is regulated in a physiologic manner in those cells and that the putative agent causing sarcoidosis does not interfere with the regulation of the TNFa gene ( figure 4 ). This concept is further corroborated by the decay of TNFa mRNA in the in vitro culture in the absence of any stimulation (figure 5).
Our observation that LPS-stimulated sarcoid AM of patients with active sarcoidosis produce significantly more TNFa than do AM of normal subjects and of those with inactive disease is in accordance with the literature and suggests that in sarcoidosis AM become primed locally (9, 13) . The increased ability to secrete TNFa after endotoxin stimulation may represent an additional marker of activation that is restricted to the lung. However, the mechanism by which sarcoid AM are primed for elevated TNFa secretion remains open. Cytokines such as interleukin-2 and y-interferon, which are produced locally by activated lung T-cells in sarcoidosis may represent the initiative agents of TNFa production. In human blood monocytes and AM, IL-2 is a strong signal for TNFa induction (2) . We therefore investigated the interrelation between IL-2 and TNFa, which are both spontaneously released in patients with active disease. Unexpectedly, we could not establish a correlation between these two parameters (r = 0.1) Eight of 21 (38%) patients released both cytokines simultaneously, whereas 7 of 21 (33%) secreted only TNFa, 3 of 21 (14%) only IL-2, and 3 of 21 (14%) neither of both. The finding of induction of TNFa by IL-2 has established an additional lymphokine-macrophage link (2), but currently the role of IL-2 in the induction of TNFa in pulmonary sarcoidosis remains a subject of speculation. In addition to the lacking correlation between IL-2 and TNFa, we could not find any correlation between TNFa and other markers of T-cell activation such as IL-2R surface expression by BAL T-lymphocytes and soluble IL-2R serum concentration, which represent useful tools for measuring T-cell activation (28) as well as clinical activity of the disease (29) . It is interesting to observe that in only 7 of 16 patients with active sarcoidosis, TNFa and IL-2 are simultaneously released by the alveolar immune cells.
Accessory functions that are provided by the cells of the mononuclear phagocytic lineage are required by most types of cellular and immune processes. The observation that these cells are compartmentalized and activated to release large amounts of monokines such as IL-1 and TNFa spontaneously therefore suggests that they participate in the pathogenesis of sarcoidosis not only as a building block in the formation of granulomata but also in the maintenance of the inflammatory processes characteristic of the disorder.
